Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cipl/p21 concomitant with a decrease in kinase activity of cyclin- dependent kinases and associated cyclins

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 1055-1064

  Zi, Xiaolin ^b   Feyes, Denise K ^b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; FLAVONOID; SILYMARIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR GROWTH;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BINDING SITES; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; G1 PHASE; HUMANS; SILYMARIN; TUMOR CELLS, CULTURED;

EID: 0031921546     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Parker, S. L., Tang, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 47: 5-27, 1996.
2. Wattenberg, L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res., 52: 2085s-2091s, 1992.
3. Morse, M. A., and Stoner, G. D. Cancer chemoprevention: principles and prospects. Carcinogenesis (Lond.), 14: 1737-1746, 1993.
4. Boone, C. W., and Wattenberg, L. W. Current strategies of cancer chemoprevention: 13th Sapporo Cancer Seminar. Cancer Res., 54: 3315-3318, 1994.
5. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Sigman C. C. Chemopreventive drug development: prospectives and progress. Cancer Epidemiol. Biomark. Prev., 3: 85-98, 1994.
6. Agarwal, R., and Mukhtar, H. Cancer chemoprevention by polyphenolic compounds present in green tea. Drug News Perspect., 8: 216-225, 1995.
7. Ames, B. N., Gold, L. S., and Willett, W. C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA, 92: 5258-5265, 1995.
8. Stoner, G. D., Morse, M. A., and Kelloff, G. J. Perspectives in cancer chemoprevention. Environ. Health Perspect., 105: 945-954, 1997.
9. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W., and Schneider, B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol., 9: 105-113, 1989.
10. Letteron, P., Labbe, G., Degott, C., Berson, A., Fromenty, B., Delaforge, M., Larrey, D., and Pessayre, D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Biochem. Pharmacol., 39: 2027-2034, 1990.
11. Ely, H. Dermatologie therapies you've probably never heard of. Derm. Clin., 7: 19-35, 1989.
12. Mereish, K. A., Bunner, D. L., Ragland, D. R., and Creasia, D. A. Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharm. Res. (N. Y.), 8: 273-277, 1991.
13. Bosisio, E., Benelli, C., and Pirola, O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol. Res., 25: 147-154, 1992.
14. Comoglio, A., Leonarduzzi, G., Carini, R., Busolin, D., Basaga, H., Albano, E., Tomasi, A., Poli, G., Morazzoni, P., and Magistretti, M. J. Studies on the antioxidant and free radical scavenging properties of IdB1016 a new flavanolignan complex. Free Radical Res. Commun., 11: 109-115, 1990.
15. Racz, K., Feher, J., Csomos, G., Varga, I., Kiss, R., and Glaz, E. An antioxidant drug, silibinin, modulates steroid secretion in human pathological adrenocortical cells. J. Endocrinol., 124: 341-345, 1990.
16. Muzes, G., Deak, G., Lang, I., Nekam, K., Gergely, P., and Feher, J. Effect of the bioflavonoid silymarin on the in vitro activity and expression of Superoxide dismutase (SOD) enzyme. Acta Physiol. Hung., 78: 3-9, 1991.
17. Mehta, R. G., and Moon, R. C. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res., 11: 593-596, 1991.
18. Agarwal, R., Katiyar, S. K., Lundgren, D. W., and Mukhtar, H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis (Lond.), 15: 1099-1103, 1994.
19. Katiyar, S. K., Korman, N. J., Mukhtar, H., and Agarwal, R. Protective effects of silymarin against photocarcinogenesis in mouse skin model. J. Natl. Cancer Inst., 89: 556-566, 1997.
20. Zi, X., Mukhtar, H., and Agarwal, R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNFα. Biochem. Biophys. Res. Commun., 239: 334-339, 1997.
21. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
22. Draetta, G. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem. Sci., 15: 378-383, 1990.
23. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
24. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
25. 1. Genes Dev., 7: 812-821, 1993.
26. 1-to-S transition in mammalian cells. Oncogene, 8: 1593-1602, 1993.
27. 1-to-S phase transition. Mol. Cell. Biol., 15: 2612-2624, 1995.
28. 1 cyclindependent kinases. Genes Dev., 9: 1149-1163, 1995.
29. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
30. Grana, X., and Reddy, P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene, 11: 211-219, 1995.
31. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
32. Polyak, K., Lee, M-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
33. 1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
34. Lee, M-H., Reynisdottir, I., and Massague, J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
35. Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., and Elledge, S. J. P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
36. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. P21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
37. 1 arrest. Cell, 76: 1013-1023, 1994.
38. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
39. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T, Bradley, A., Olson, E. N., Harper, J. W., and Elledge, S. J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
40. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocytes/macrophage differentiation. Cancer Res., 55: 668-674, 1995.
41. Zhang, H., Hannon, G., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750-1758, 1994.
42. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., Swindell, E., Fox, M. P., and Wei, N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
43. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
44. Chen, J. Y., Funk, W. D., Wright, W. E., Shay, J. W., and Minna J. D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene, 8: 2159-2166, 1993.
45. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.
46. Weinstein, I. B. relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J. Cell. Biochem., 25S: 23-28, 1996.
47. Blagosklonny, M. V., Prabhu, N. S., and El-Deiry, W. S. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res., 57: 320-325, 1997.
48. El-Deiry, W. S., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Topological control of p21WAF1/ CIP1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
49. Russo, T., Zambrano, N., Esposito, F., Ammendola, R., Cimino, F., Fiscella, M., Jackman, J., O'Connor, P. M., Anderson, C. W., and Appella, E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem., 270: 29386-29391, 1995.
50. Gartenhaus, R. B., Wang, P., and Hoffmann, P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. USA, 93: 265-268, 1996.
51. Li, X-S., Rishi, A. K., Shao, Z-M., Dawson, M. I., Jong, L., Shroot, B., Reichert, U., Ordonez, J., and Fontana, J. A. Post-transcriptional regulation of p21WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res., 56: 5055-5062, 1996.
52. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
53. Elledge, S. J., and Harper, J. W. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 847-852, 1994.
54. Jiang, H., Lin, J., Su, Z-Z., Collatrt, F. R., Huberman, E., and Fisher, P. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/Cip1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
55. Goldberg, Y., Nassif, I. I., Pittas, A., Tsai, L-L., Dynlacht, B. D., Rigas, B., and Shiff, S. J. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene, 12: 893-901, 1996.
56. 1 cyclin (Cln) function in yeast. Cell, 66: 1197-1206, 1991.
57. 1 phase of the cell cycle. Cell, 65: 701-713, 1991.
58. Motokura, T., Bloom, T., Kim, H. G., Juppner, H., Ruderman, J. V., Kronenberg, H. M., and Arnold, A. A novel cyclin encoded by a bell-linked candidate oncogene. Nature (Lond.), 350: 512-515, 1991.
59. Xiong, Y., Connolly, T., Futcher, B., and Beach, D. Human D-type cyclin. Cell, 65: 691-699, 1991.
60. 1-S phase protein kinase. Science (Washington DC), 257: 1958-1961, 1992.
61. Jiang, W., Kahn, S. M., Zhou, P., Zhang, Y-J., Cacace, A. M., Infante, A. S., Doi, S., Santella, R. M., and Weinstein, I. B. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene, 8: 3447-3457, 1993.
62. Lammie, G. A., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michalides, R., Dickson, C., Arnold, A., and Peters, G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene, 6: 439-444, 1991.
63. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
64. Tsuruta, H., Sakamoto, H., Onda, M., and Terada, M. Amplification and overexpression of EXP1 and EXP2/cyclin D1 genes in human esophageal carcinomas. Biochem. Biophys. Res. Commun., 196: 1529-1536, 1993.
65. Arber, N., Doki, Y., Han, E. K-H., Sgambato, A., Zhou, P., Kim, N-H., Delohery, T., Klein, M. G., Holt, P. R., and Weinstein, I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res., 57: 1569-1574, 1997.
66. Li, Y., Jenkins, C. W., Nichols, M. A., and Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene, 9: 2261-2268, 1994.
67. 1 progression. Oncogene, 9: 2663-2674, 1994.